STAT+: Startup Spotlight: Vigil Neuroscience hopes to eventually target the rare disease ALSP
Vigil Neuroscience has revealed the first condition that it will target: a rare, genetic neurodegenerative disorder called ALSP, or adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
The Cambridge, Mass.-based company, which bought the rights to all its current drug candidates from Amgen, also announced a $90 million series B financing round on Wednesday.
